Law
Offices of Howard G. Smith announces the filing of a class action
lawsuit on behalf of investors of Clovis Oncology, Inc. ("Clovis" or the
"Company") (NYSE:CLVS) who purchased shares between October 31, 2013 and
November 15, 2015, inclusive (the “Class Period”). Clovis investors have
until January 19, 2016 to file a lead plaintiff motion.
Clovis is a biopharmaceutical company that focuses on acquiring,
developing, and commercializing innovative anti-cancer agents in the
United States, Europe and additional international markets.
Throughout the Class Period, Defendants made false and/or misleading
statements, as well as failed to disclose material adverse facts about
the Company’s business, operations, and prospects. Specifically,
Defendants made false and/or misleading statements and/or failed to
disclose: (1) that the New Drug Application (“NDA”) that Clovis
submitted to the FDA for rociletinib contained immature data sets based
on both unconfirmed response rates and confirmed response rates; (2)
that Clovis’ Breakthrough Therapy designation submission contained
immature data set based primarily on unconfirmed responses; (3) that
Clovis presented interim data publicly and at medical meetings that
included a data set based primarily on unconfirmed responses; (4) that
as the efficacy data matured, the number of patients with an unconfirmed
response who converted to a confirmed response was lower than expected;
(5) that, as a result of the foregoing, Clovis’ NDA was likely to be
delayed and/or rejected by the FDA; and (6) that, as a result of the
foregoing, the Defendants’ statements about Clovis’ business,
operations, and prospects, were false and misleading and/or lacked a
reasonable basis.
If you purchased Clovis securities during the Class Period, and wish to
learn more about this action, or if you have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Howard G. Smith, Esquire, of Law Offices of
Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania
19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by
email to howardsmith@howardsmithlaw.com,
or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151123006233/en/
Copyright Business Wire 2015